使用扫描源OCT血管成像观察非渗出性年龄相关性黄斑变性中亚临床新生血管的自然史
前瞻性观察性连续病例系列纳入160例一眼为中晚期AMD或地图状萎缩、对侧眼为渗出性AMD的患者,用扫描源OCT血管成像检测亚临床黄斑新生血管(MNV)。首次成像时亚临床MNV患病率为14.4%,12个月时全部134眼渗出累积发生率为6.8%,有亚临床MNV眼为21.1%,无亚临床MNV眼为3.6%。检出亚临床MNV后渗出风险为无亚临床MNV眼的15.2倍(95%CI 4.2-55.4)。作者建议对亚临床MNV眼增加随访频次和家庭监测,在开展前瞻性研究前不推荐玻璃体内治疗。
要点
- 首次扫描源OCT血管成像时亚临床MNV患病率为14.4%(23/160眼)。
- 12个月时全部134眼渗出累积发生率为6.8%,有亚临床MNV眼为21.1%,无亚临床MNV眼为3.6%。
- 检出亚临床MNV后渗出风险为无亚临床MNV眼的15.2倍(95%CI 4.2-55.4)。
核心结论
- 至12个月时,有明确亚临床MNV的眼渗出风险高于未检测到MNV的眼。
- 作者建议对亚临床MNV眼增加随访频次和家庭监测,在开展前瞻性研究前不推荐玻璃体内治疗。
研究设计与样本
- 前瞻性、观察性、连续病例系列。
- 纳入160例患者,其中一眼为iAMD(110眼)或继发于非渗出性AMD的地图状萎缩(50眼),对侧眼为渗出性AMD。
- 所有患者均使用3×3 mm和6×6 mm扫描源OCT血管成像(PLEX Elite 9000;Carl Zeiss Meditec, Inc, Dublin, CA)成像。
- 检测MNV的en face slab从外层视网膜延伸至脉络膜毛细血管层,使用专有算法去除投影伪影。
- 主要结局指标为亚临床MNV患病率及至渗出的时间,采用Kaplan-Meier法估算1年渗出累积发生率。
主要发现
- 2014年8月至2017年3月,160例患者接受扫描源OCT血管成像,其中iAMD 110眼、地图状萎缩50眼。
- 首次成像时23/160眼检测到亚临床MNV,患病率为14.4%。
- 随访期间6眼出现亚临床MNV。
- 134眼有随访,其中13眼出现渗出,这13眼中10眼存在预先存在的亚临床MNV。
- 至12个月,全部134眼Kaplan-Meier渗出累积发生率为6.8%;首次成像时有亚临床MNV眼为21.1%,无亚临床MNV眼为3.6%。
关键数值与推荐
- 亚临床MNV患病率:14.4%(23/160眼)。
- 12个月全部134眼渗出累积发生率:6.8%。
- 12个月有亚临床MNV眼渗出累积发生率:21.1%;无亚临床MNV眼:3.6%。
- iAMD眼与地图状萎缩眼预先存在MNV的渗出累积发生率比较:P = 0.847(log-rank检验)。
- 检出亚临床MNV后渗出风险:为无亚临床MNV眼的15.2倍(95%CI 4.2-55.4)。
临床怎么用
- 作者建议对亚临床MNV眼增加随访频次和家庭监测。
- 作者不推荐在开展前瞻性研究前进行玻璃体内治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Swept-source (SS) OCT angiography (OCTA) was used to determine the prevalence, incidence, and natural history of subclinical macular neovascularization (MNV) in eyes with nonexudative age-related macular degeneration (AMD). DESIGN: Prospective, observational, consecutive case series. PARTICIPANTS: Patients with intermediate AMD (iAMD) or geographic atrophy (GA) secondary to nonexudative AMD in 1 eye and exudative AMD in the fellow eye. METHODS: All patients were imaged using both the 3×3 mm and 6×6 mm SS OCTA fields of view (PLEX Elite 9000; Carl Zeiss Meditec, Inc, Dublin, CA). The en face slab used to detect the MNV extended from the outer retina to the choriocapillaris, and projection artifacts were removed using a proprietary algorithm. MAIN OUTCOME MEASURES: Prevalence of subclinical MNV and time to exudation with Kaplan-Meier cumulative estimates of exudation at 1 year. RESULTS: From August 2014 through March 2017, 160 patients underwent SS OCTA (110 eyes with iAMD and 50 eyes with GA). Swept-source OCTA identified subclinical MNV at the time of first imaging in 23 of 160 eyes, for a prevalence of 14.4%. Six eyes demonstrated subclinical MNV during the follow-up. Of 134 eyes with follow-up visits, a total of 13 eyes demonstrated exudation, and of these 13 eyes, 10 eyes were found to have pre-existing subclinical MNV. By 12 months, the Kaplan-Meier cumulative incidence of exudation for all 134 eyes was 6.8%. For eyes with subclinical MNV at the time of first SS OCTA imaging, the incidence was 21.1%, and for eyes without subclinical MNV, the incidence was 3.6%. There was no difference in the cumulative incidence of exudation from pre-existing MNV in eyes with iAMD or GA (P = 0.847, log-rank test). After the detection of subclinical MNV, the risk of exudation was 15.2 times (95% confidence interval, 4.2-55.4) greater compared with eyes without subclinical MNV. CONCLUSIONS: By 12 months, the risk of exudation was greater for eyes with documented subclinical MNV compared with eyes without detectable MNV. For eyes with subclinical MNV, recommendations include more frequent follow-up and home monitoring. Intravitreal therapy is not recommended until prospective studies are performed.
引用
- de Oliveira Dias JR, Zhang Q, Garcia JMB, et al. Natural History of Subclinical Neovascularization in Nonexudative Age-Related Macular Degeneration Using Swept-Source OCT Angiography. Ophthalmology. 2017. PMID: 28964581. doi:10.1016/j.ophtha.2017.08.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。